← 返回

通过光流控分析在单细胞分辨率下评估 CAR-T 细胞的多模态功能

英文原题:Evaluating Multimodal Functionality of Chimeric Antigen Receptor T Cells at Single-Cell Resolution through Optofluidics Analysis.

查看英文原题

Evaluating Multimodal Functionality of Chimeric Antigen Receptor T Cells at Single-Cell Resolution through Optofluidics Analysis.

PubMed 2026/04/21(内容时间) J Vis Exp Q3 · IF 1.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过继性 T 细胞疗法是一种新型治疗模式:先对患者自体 T 细胞进行基因改造,使其表达靶向肿瘤的嵌合抗原受体(CAR),再于体外扩增并回输患者体内。尽管该疗法在晚期血液系统恶性肿瘤患者中显示出显著抗肿瘤效力,仍有相当一部分患者未能获得持久应答。临床结局差异可能由多种个体因素导致,越来越多证据表明,输注前 CAR-T 产品中多功能 T 细胞所占比例与癌症缓解持久性密切相关。然而,目前 CAR-T 产品的常规评估依赖群体平均测量或终点检测,限制了对功能更强的细胞亚群进行分离和研究。本研究展示了一套工作流程,利用光流控平台评估单个 CAR-T 细胞的细胞因子分泌谱及 CD137 表达所反映的活化状态,并可选择加入细胞毒活性评估。多模式功能最强的细胞可被分离用于进一步分析,从而为下一代 CAR-T 细胞疗法设计提供依据。

展开英文摘要原文

Adoptive T-cell therapy is a novel treatment paradigm in which autologous T cells are genetically modified to express a tumor-targeting chimeric antigen receptor (CAR) prior to ex vivo expansion and re-infusion into the patient. Despite remarkable demonstrations of anti-tumor potency in patients with advanced hematological malignancies, long-lasting responses fail to manifest in a substantial fraction of cases.

Although several idiosyncratic factors may contribute to the variability in clinical outcomes, there is mounting evidence that the percentage of polyfunctional T cells in the pre-infusion CAR-T cell product strongly correlates with the durability of cancer remission. Unfortunately, standard evaluations of CAR-T cell products currently rely on bulk population measurements or terminal assays, limiting the ability to isolate and study sub-populations with heightened functional properties.

Here, we demonstrate a workflow that leverages an optofluidics platform to evaluate both the cytokine secretion profile and activation via CD137 expression of individual CAR-T cells, which can be optionally combined with cytotoxic activity assessment. Cells exhibiting the greatest degree of multimodal functionality can be isolated for further analyses to inform the design of next-generation CAR-T cell therapies.

论文信息

作者
Franz J、Freitag F、Ho P、Bormann T、Hudecek M、Luu M
第一作者单位
Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg.
通讯作者单位
Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg; Außenstelle Zelluläre Immuntherapie, Fraunhofer Institut für Zelltherapie und Immunologie (IZI); Luu_M@kw.de.
文献类型
音视频资料 · 非美国政府资助研究
期刊
Journal of visualized experiments : JoVE2026 Apr 21
原文标识
PubMed 42113812 · DOI 10.3791/69702